Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood and tissue samples sought to refine cancer DNA tests

NCT ID NCT07318051

Knowledge-focused Sponsor: Natera, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study collects blood and leftover tissue samples from 9,600 people with various cancers, including breast, lung, and pancreatic cancer. Researchers will use these samples to improve tests that look for cancer DNA in the blood. The goal is to better detect if cancer returns or how well treatment is working.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better blood tests to detect cancer recurrence or monitor treatment response across many cancer types.
What could go wrong
This is an observational sample collection study, not a treatment trial. It does not test a therapy, so it cannot directly improve patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 9,600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Jan 2035

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants 18 years of age or older diagnosed with malignant, invasive solid tumors prior to receiving treatment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. 18 years of age or older. 2. Any patient that has an untreated primary solid malignancy within the following cohorts: 1. Breast cancer 2. Lung cancer 3. Muscle invasive bladder cancer 4. Rectal cancer 5. Pancreatic cancer 6. Ovarian cancer 7. Gastroesophageal cancer 8. Prostate cancer 9. Melanoma 10. Hepatic/liver cancer 11. Uterine/endometrial cancer 12. Head and neck Cancer 3. The participant has a suspected primary malignancy of pancreatic, endometrial, bladder, or ovarian cancer based on imaging. 4. Eastern Cooperative Oncology Group performance status ≤ 2. 5. Able to tolerate venipuncture for research blood draw(s). 6. Consent to provide residual tumor tissue for research. 7. Willing and able to comply with the study requirements. 8. Signed informed consent(s) must be obtained prior to participation in the study. Exclusion Criteria: 1. Pregnant or breastfeeding. 2. Prior history and treatment for any cancer within the past year or has another active cancer, with the exception of participants who have undergone surgical removal of skin squamous cell or basal cell cancers. 3. Has initiated postoperative systemic treatment. 4. At time of enrollment, has undergone or plans to undergo any ctDNA testing to assess molecular residual disease, with the exception of comprehensive genomic profiling for therapeutic selection. 5. History of bone marrow or organ transplant. 6. Serious medical conditions that may adversely affect ability to participate in the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm endometrial cancer gastroesophageal cancer head and neck cancer Head and Neck Neoplasms infiltrating bladder urothelial carcinoma liver cancer Liver Neoplasms lung cancer lung neoplasm malignant pancreatic neoplasm melanoma ovarian cancer pancreatic neoplasm prostate cancer rectal cancer rectal neoplasm uterine cancer uterine corpus cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Gastroesophageal cancer Head and neck cancer Hepatic/liver cancer Liver cancer Lung cancer Melanoma Muscle invasive bladder cancer Ovarian cancer Pancreatic cancer Prostate cancer Rectal cancer Uterine cancer Uterine endometrial cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Natera, Inc.

    RECRUITING

    Austin, Texas, 78753, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.